These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29459430)

  • 1. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
    Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
    Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Experience with Anti-tumor Necrosis factor - α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis.
    Corredores Dieb J; Vofo B; Amer R
    Ocul Immunol Inflamm; 2024 Aug; 32(6):932-939. PubMed ID: 36538811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM
    Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation.
    Evereklioglu C; Sonmez HK; Sevim DG; Arda H; Sener H; Polat OA; Horozoglu F
    Int Ophthalmol; 2023 Dec; 43(12):4461-4472. PubMed ID: 37555889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.
    Goto H; Zako M; Namba K; Hashida N; Kaburaki T; Miyazaki M; Sonoda KH; Abe T; Mizuki N; Kamoi K; Brézin AP; Dick AD; Jaffe GJ; Nguyen QD; Inomata N; Kwatra NV; Camez A; Song AP; Kron M; Tari S; Ohno S
    Ocul Immunol Inflamm; 2019; 27(1):40-50. PubMed ID: 30015528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
    Park SE; Jun JW; Lee DH; Lee SC; Kim M
    Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
    Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
    Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis.
    Choe S; Heo JW; Oh BL
    Korean J Ophthalmol; 2020 Aug; 34(4):274-280. PubMed ID: 32783419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing biological disease modifying treatment for paediatric uveitis in the real world.
    Oh LJ; Nguyen CL; Phan K; Wong E; Zagora S; Singh-Grewal D; Chaitow J; Grigg JR; McCluskey P
    Clin Exp Ophthalmol; 2019 Aug; 47(6):741-748. PubMed ID: 30834650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab in Patients with Active Noninfectious Uveitis.
    Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
    N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
    Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
    Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pediatric uveitis with adalimumab: the MERSI experience.
    Castiblanco C; Meese H; Foster CS
    J AAPOS; 2016 Apr; 20(2):145-7. PubMed ID: 27079596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.